A Protocol of Irinotecan for Carcinoma of the Lung
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | July 27, 2012 | ||||
Last Updated Date | August 31, 2012 | ||||
Start Date ICMJE | September 2012 | ||||
Estimated Primary Completion Date | September 2013 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Progression-free survival following irinotecan therapy [ Time Frame: up to five years after initiation of protocol therapy ] [ Designated as safety issue: No ] Progression-free survival following irinotecan therapy |
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT01654081 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE | |||||
Original Secondary Outcome Measures ICMJE | |||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | A Protocol of Irinotecan for Carcinoma of the Lung | ||||
Official Title ICMJE | A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung | ||||
Brief Summary | The goal of this trial is to demonstrate the potential clinical benefit of irinotecan chemotherapy in patients with a specific NSCLC phenotype, ISG15-positive. The use of irinotecan in subjects with ISG15-positive NSCLC will be associated with an improved rate of clinical benefit (objective response, disease stability, and time to progression) compared to historical controls that were not previously selected for ISG-15 expression. |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 2 | ||||
Study Design ICMJE | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE | Lung Cancer | ||||
Intervention ICMJE | Drug: Irinotecan
Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle |
||||
Study Arm (s) | Experimental: Irinotecan
Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
Intervention: Drug: Irinotecan |
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Not yet recruiting | ||||
Estimated Enrollment ICMJE | 20 | ||||
Estimated Completion Date | September 2014 | ||||
Estimated Primary Completion Date | September 2013 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
The effects of Irinotecan on the developing human fetus are unknown. For this reason and because camptothecins are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of irinotecan administration. Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE |
|
||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT01654081 | ||||
Other Study ID Numbers ICMJE | 11-LUN-90-MCC | ||||
Has Data Monitoring Committee | Yes | ||||
Responsible Party | University of Kentucky | ||||
Study Sponsor ICMJE | University of Kentucky | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | University of Kentucky | ||||
Verification Date | August 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |